At a glance
ClinicalIndex Comparison RecordPhase 4Completed
Drug / intervention
nevirapine, stavudine, lamivudinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparison of the Steady State Pharmacokinetics of Nevirapine, Stavudine Plus Lamivudine in HIV Positive Ugandan Patients Taking Triomune 40 With the Pharmacokinetics of the Originator Products.
In Brief
A Phase 4 clinical trial evaluating nevirapine, stavudine, lamivudine for HIV Infections. Completed, across 1 site.
Detailed Summary
This study aims to compare the steady state pharmacokinetics of stavudine, lamivudine, and nevirapine in HIV positive Ugandan patients taking Triomune 40 with the pharmacokinetics of the originator products known as Viramune, Epivir and Zerit 40.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesUganda
CollaboratorsDepartment of Foreign Affairs, Ireland
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2007
First PostedApr 2007
Primary CompletionMay 2007
Study CompletionNov 2007
TodayJul 2026
First PostedApr 3, 2007
Enrollment StartJan 1, 2007
Primary CompletionMay 1, 2007
Study CompletionNov 1, 2007
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 19.2 years ago
Interventions
nevirapine, stavudine, lamivudinedrug